Cost-Benefit Decisions Will Reside With Docs/Patients, Not CMS, McClellan Says
This article was originally published in The Pink Sheet Daily
Doctors and patients will consider cost-effectiveness in choosing treatment options that will result in health care efficiencies without the Centers for Medicare & Medicaid Services needing to incorporate such criteria into coverage decisions, Administrator McClellan suggests.
You may also be interested in...
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?
The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.